Tech Review

Future challenges in biomanufacturing

22.08.2011

Outsourcing is one of the biggest global trends in the biopharmaceutical industry. It is taking more and more specific know-how to master the challenges posed by manufacturing of biologics, which include rising price and cost pressures, the need for high flexibility, and the ever-shifting (and in most cases

growing) regulatory requirements for biomanufacturing. This article will give you an overview of how a contract manufacturing organisation (CMO) with many years of experience in manufacturing several classes of bio­pharmaceuticals is positioning itself to face these challenges.

In the maturing biopharmaceutical industry today, there is increasing competition to innovative pipelines from me-too products, biobetters and biosimilars. The pressure on the cost of goods (COG) is therefore increasing. And to reduce COG, each manufacturing facility needs to meet the specific requirements for a new project regarding the technical instrumentation even before the project enters its initial stages. This will reduce investment and later depreciation, which impact negatively on costs. At the same time, it is important to be able to maintain as much flexibility as possible in order to comply with upcoming regulatory requirements. Thus CMOs need to invest constantly in the development and establishment of new manufacturing technologies and the necessary equipment.

Implementation of new

process technologies

At Richter-Helm, the investment in new technology does not focus only on adding new (greater) manufacturing scales, although this is often a first reaction to COG pressure. Many firms consider

decreasing costs by increasing scale.
But a good alternative to simple scale-up is the implementation of new process technologies that can achieve higher yields, while at the same time improving quality or process robustness – at least for certain processing steps. Over the past few years, the biomanufacturing industry has made substantial improvements in expression and fermentation technologies. In terms of microbial production, innovative E. coli expression systems combined with high density fermentation regimes can lead to yields up to 20g of the target protein per litre of fermentation broth – as was recently accomplished by Richter-Helm for a fusion protein process[1].
In addition to high product yields, in many cases it is also important to find the appropriate expression system for high-quality products that show no or only low expression rates in E. coli. In these cases, the use of other bacterial expression hosts such as Bacillus or Pseudomonas strains can help. Pichia pastoris technology is another option for dealing with even more complex proteins such as enzymes or antibody fragments. A multipurpose facility for manufacturing bio­pharmaceuticals therefore needs to be equipped to take advantage of all these expression systems in order to be able to reduce upfront investment costs from the outset.
New expression systems lead to high primary product yields, and these need to be dealt with in purification processes. Thus optimisation of the downstream processes is also necessary. A recent study showed that the implementation of EBA technology can reduce total process cost by up to 56%[2]. Other new purification technologies that can be implemented include multi­column counter current solvent gradient purification (MCSGP), which reduces the loss of product in chromatography steps.
An ongoing trend in biopharmaceutical product development is the covalent modification of proteins by chemical or enzymatic cross linking (e.g. PEGylation, HESylation, Polyasialation) to increase the half-life of those products in humans. These technologies therefore need to be accessible in a multipurpose facility as well.

Expert project management

Of course, all of the technologies mentioned above also need to be scalable. For a CMO to offer customers the option of going from bench to market with a single manufacturer, it is important to offer more than one scale. For instance, at Richter-Helm three different manufacturing scales are available (lab, pilot, large) to implement each project at the best matching scale while limiting costs for large equipment or a higher number of batches (Fig. 1).
But a CMO does not only need sufficient technical capabilities to serve the future needs of its customers. Professional project execution is also a major success factor. It is extremely important for a CMO to be prepared for the fact that different customers have different requirements, as they range from small start-ups to big pharma. The project approach, for example regarding the regulatory consultancy required, will be extremely dependent on the customer’s situation (Fig. 2). Project management that ensures close collaboration and communication between all parties is becoming increasingly important, driven by the trend towards long-lasting partnerships and strategic alliances between developers and manufacturers.D


References
[1] Kaiser et al., Steigerung von Qualität und Ausbeute in der Wirkstoffproduktion; Laborwelt 11 (3), 18-22, 2010
[2] May, Pohlmeyer; Improving Process Economy with Expanded-Bed Adsorption Technology, BioProcess International, January 2011

Contact
Dr. Kai Pohlmeyer
Dr.-Ing. Philipp Göpel
Richter-Helm BioTec GmbH & Co. KG
Nordkanalstrasse 28
20097 Hamburg, Germany
Tel.: +49 40 2375-0
k.pohlmeyer@richter-helm-biotec.eu
p.goepel@richter-helm-biotec.eu
www.richter-helm-biotec.eu

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/article/future-challenges-in-biomanufacturing.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • EPIGENOMICS3.83 EUR23.5%
  • PAION3.05 EUR23.0%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-15.5%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 20.09.2014


Current issue

All issues

Product of the week

Products